W1339 Safe Anti-Ulcer Peptide, in Trial for Inflammatory Bowel Desease, Stable Gastric Pentadecapeptide BPC 157 (PL14736) Can Cure Rats With Short Bowel Syndrome Complicated With Ulcerative Colitis

The small intestine is key in the digestion and absorption of macro and micronutrients. The large intestine is essential for the absorption of water, to allow adequate defecation, and to harbor intestinal microbiota, for which their nutritional role is as important as it is unknown. This article will describe the causes and consequences of malnutrition in patients with inflammatory bowel diseases, the importance of screening and replacement of micronutrient deficits, and the main indications for enteral and parenteral nutrition in these patients. We will also discuss the causes of short bowel syndrome, a complex entity due to anatomical or functional loss of part of the small bowel, which can cause insufficient absorption of liquid, electrolytes, and nutrients and lead to complex management. Finally, we will review the causes, consequences, and management of malnutrition in patients with malignant and benign digestive tumors, including neuroendocrine tumors (present not only in the intestine but also in the pancreas).

Download Full-text

Fecal microbiota transplantation. Prospects in pediatric practice

Voprosy detskoj dietologii ◽

10.20953/1727-5784-2021-3-37-45 ◽

2021 ◽

Vol 19 (3) ◽

pp. 37-45

Author(s):

E.S. Pimenova ◽

◽

E.M. Mukhametova ◽

E.Ya. Musaeva ◽

S.I. Erdes ◽

...

Keyword(s):

Irritable Bowel Syndrome ◽

Clostridium Difficile ◽

Short Bowel Syndrome ◽

Fecal Microbiota Transplantation ◽

Fecal Microbiota ◽

Pediatric Practice ◽

Short Bowel ◽

Bowel Diseases ◽

Inflammatory Bowel ◽

Irritable Bowel

The aim of this review is to summarize data on the experience of using fecal microbiota transplantation (FMT) as a method of treating intestinal diseases, in particular in pediatric practice. FMT is the process of transferring fecal material from a healthy donor to the recipient’s gastrointestinal tract in order to alter gut microbial composition. To date, the most amount of research has been conducted in the field of treatment for Clostridium difficile infection. The mortality rate among children with this pathology is 1–5%. Randomized clinical trials show a higher efficacy of FMT compared to the use of antibiotics (efficacy rates of 90% and 26%, respectively) in the treatment for C. difficile infection. The effectiveness of FMT as a treatment for other diseases has been discussed. Cases of the successful use of FMT as a treatment for short bowel syndrome in children have been described, and studies on the effectiveness of this technique in patients with irritable bowel syndrome and inflammatory bowel diseases have been conducted. Most studies have been carried out on small samples of patients, and the results vary. The potential of using FMT as a treatment of children with severe bowel diseases is high, which makes it necessary to conduct further research in pediatric practice. Key words: inflammatory bowel disease, Clostridium difficile infection, short bowel syndrome, irritable bowel syndrome, fecal microbiota transplantation

Download Full-text

Effects of Diclofenac, L-NAME, L-Arginine, and Pentadecapeptide BPC 157 on Gastrointestinal, Liver, and Brain Lesions, Failed Anastomosis, and Intestinal Adaptation Deterioration in 24 Hour-Short-Bowel Rats

PLoS ONE ◽

10.1371/journal.pone.0162590 ◽

2016 ◽

Vol 11 (9) ◽

pp. e0162590 ◽

Cited By ~ 18

Author(s):

Nermin Lojo ◽

Zarko Rasic ◽

Anita Zenko Sever ◽

Danijela Kolenc ◽

Darko Vukusic ◽

...

Keyword(s):

Intestinal Adaptation ◽

Brain Lesions ◽

Short Bowel ◽

Bpc 157 ◽

Pentadecapeptide Bpc 157

Download Full-text

Stable Gastric Pentadecapeptide BPC 157 in Trials for Inflammatory Bowel Disease (PL-10, PLD-116, PL14736, Pliva, Croatia) Heals Ileoileal Anastomosis in the Rat

Surgery Today ◽

10.1007/s00595-006-3498-9 ◽

2007 ◽

Vol 37 (9) ◽

pp. 768-777 ◽

Cited By ~ 18

Author(s):

Tihomir Vuksic ◽

Ivan Zoricic ◽

Luka Brcic ◽

Marko Sever ◽

Robert Klicek ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Bpc 157 ◽

Pentadecapeptide Bpc 157 ◽

Inflammatory Bowel

Download Full-text

Focus on Ulcerative Colitis: Stable Gastric Pentadecapeptide BPC 157

Current Medicinal Chemistry ◽

10.2174/092986712803414015 ◽

2012 ◽

Vol 19 (1) ◽

pp. 126-132 ◽

Cited By ~ 24

Author(s):

P. Sikiric ◽

S. Seiwerth ◽

R. Rucman ◽

B. Turkovic ◽

D. S. Rokotov ◽

...

Keyword(s):

Ulcerative Colitis ◽

Bpc 157 ◽

Pentadecapeptide Bpc 157

Download Full-text

Impact of teduglutide, a GLP-2 agonist, on inflammatory bowel disease-associated short bowel syndrome: a tertiary single-center study

Clinical Nutrition ESPEN ◽

10.1016/j.clnesp.2021.09.362 ◽

2021 ◽

Vol 46 ◽

pp. S671

Author(s):

M. de Seze ◽

B. de Dreuille ◽

L. Billiauws ◽

J. Bettolo ◽

C. Hutinet ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Short Bowel Syndrome ◽

Bowel Disease ◽

Single Center ◽

Short Bowel ◽

Single Center Study ◽

Inflammatory Bowel ◽

Center Study

Download Full-text

Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy

Current Pharmaceutical Design ◽

10.2174/1381612826666200424180139 ◽

2020 ◽

Vol 26 (25) ◽

pp. 2991-3000 ◽

Cited By ~ 1

Author(s):

Predrag Sikiric ◽

Domagoj Drmic ◽

Marko Sever ◽

Robert Klicek ◽

Alenka B. Blagaic ◽

...

Keyword(s):

Ulcerative Colitis ◽

Gastrointestinal Tract ◽

Corneal Ulcer ◽

Bowel Resection ◽

Bpc 157 ◽

Beneficial Effects ◽

Duodenal Lesions ◽

Pentadecapeptide Bpc 157 ◽

Large Bowel Resection ◽

Entire Gastrointestinal Tract

This review is focused on the healing of fistulas and stable gastric pentadecapeptide BPC 157. Assuming that the healing of the various wounds is essential also for the gastrointestinal fistulas healing, the healing effect on fistulas in rats, consistently noted with the stable gastric pentadecapeptide BPC 157, may raise several interesting possibilities. BPC 157 is originally an anti-ulcer agent, native to and stable in human gastric juice (for more than 24 h). Likely, it is a novel mediator of Robert’s cytoprotection maintaining gastrointestinal mucosal integrity. Namely, it is effective in the whole gastrointestinal tract, and heals various wounds (i.e., skin, muscle, tendon, ligament, bone; ulcers in the entire gastrointestinal tract; corneal ulcer); LD1 is not achieved. It is used in ulcerative colitis clinical trials, and now in multiple sclerosis, and addressed in several reviews. Therefore, it is not surprising that BPC 157 has documented consistent healing of the various gastrointestinal fistulas, external (esophagocutaneous, gastrocutaneous, duodenocutaneous, colocutaneous) and internal (colovesical, rectovaginal). Taking fistulas as a pathological connection, this rescue is verified with the beneficial effects in rats with the various gastrointestinal anastomoses, esophagogastric, jejunoileal, colo-colonic, ileoileal, esophagojejunal, esophagoduodenal, and gastrojejunal. This beneficial effect occurs equally when the gastrointestinal anastomoses are impaired with the application of NSAIDs, cysteamine, large bowel resection, as well as concomitant esophageal, gastric, and duodenal lesions and/or ulcerative colitis presentation, short bowel syndrome progression, liver and brain disturbances presentation. Particular aspects of the BPC 157 healing of the fistulas are especially emphasized.

Download Full-text